TMDD Model
Indication: HER2-positive Breast Cancer
Interactive Trastuzumab PBPK-TMDD simulator showing how shed HER2 antigen (ECD HER2) affects drug pharmacokinetics and receptor occupancy. Based on the Shah (2013) minimal PBPK model with target shedding.
Drug Overview
Clinical Context
- Molecular Target
- HER2 (ErbB2) — membrane-bound and soluble ECD forms
- Drug Class
- Monoclonal Antibody (Anti-HER2)
- Therapeutic Area
- Oncology
- Indication
- HER2-positive Breast Cancer
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Minimal PBPK-TMDD with Target Shedding
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for TMDD Model allows you to explore concentration-time profiles under different dosing scenarios. The underlying Minimal PBPK-TMDD with Target Shedding model characterizes the pharmacokinetics of this monoclonal antibody (anti-her2) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the TMDD Model PK simulator?
This is a free, interactive pharmacokinetic simulator for TMDD Model used in HER2-positive Breast Cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does TMDD Model belong to?
TMDD Model is classified as a Monoclonal Antibody (Anti-HER2) that targets HER2 (ErbB2) — membrane-bound and soluble ECD forms. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of TMDD Model. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Minimal PBPK-TMDD with Target Shedding model. PBPK models use physiological parameters to predict drug distribution across tissues and organs.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
Capecitabine and 5-FU
Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
PBPK-PD of ADCs
Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy
Ready to Simulate?
Launch the TMDD Model simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community